Drug Trial Radar · NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
910
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Jan 8, 2029
Study completion Jan 8, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken alone or together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab with or without capecitabine, with zanidatamab with or without docetaxel, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken alone or together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Metastatic Breast Cancer
- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
- Colorectal Cancer
Interventions
ZongertinibDrug
Zongertinib
Trastuzumab deruxtecanDrug
Trastuzumab deruxtecan
Trastuzumab emtansineDrug
Trastuzumab emtansine
TrastuzumabDrug
Trastuzumab
CapecitabineDrug
Capecitabine
mFOLFOX6Drug
mFOLFOX6 (oxaliplatin, calcium folinate, 5-fluorouracil)
zanidatamabDrug
zanidatamab
DocetaxelDrug
Docetaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: up to 21 days
- Dose optimization and justification (Phase II): Objective response (OR)Time frame: up to 50 months
Locations
105 sites in 10 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope and Innovation
Cerritos, California · Recruiting
Ellison Medical Institute
Los Angeles, California · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
University of California Irvine
Orange, California · Recruiting
Sharp Memorial Hospital
San Diego, California · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Helios CR Inc
Lakeland, Florida · Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Orchard Healthcare Research Inc.- Skokie
Skokie, Illinois · Recruiting
Community Health Network
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Not yet recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
New York Cancer & Blood Specialists
Shirley, New York · Recruiting
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
Baptist Cancer Center - Memphis
Memphis, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Tennessee Oncology, Pllc
Nashville, Tennessee · Recruiting
The Methodist Hospital Research Institute
Houston, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Hôpital Vivalia De Libramont
Libramont-Chevigny, Belgium · Recruiting
Centre Hospitalier Universitaire de Liège
Liège, Belgium · Terminated
CHU UCL Namur
Namur, Belgium · Recruiting
Jilin Province Cancer Hospital
Changchun, China · Recruiting
The First Hospital of Jilin University
Changchun, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Jiangsu Province Hospital
Nanjing, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Tianjin Cancer Hospital
Tianjin, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.